Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination

被引：42
作者：
Legout, L.
Senneville, E.
Stern, R.
Yazdanpanah, Y.
Savage, C.
Roussel-Delvalez, M.
Rosele, B.
Migaud, H.
Mouton, Y.
机构：
[1] Univ Lille, Dron Hosp, Div Infect Dis, Tourcoing, France
[2] Univ Hosp Geneva, Geneva, Switzerland
[3] Univ Lille, Salengro Hosp, Dept Microbiol, Lille, France
[4] Univ Lille, Salengro Hosp, Dept Orthopaed Surg, Lille, France
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2006年 / 12卷 / 10期
关键词：
bone infections; cefepime; fluoroquinolone; Gram-negative bacteria; joint infections; treatment;
D O I：
10.1111/j.1469-0691.2006.01523.x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
A 3-year retrospective study evaluated the effectiveness and safety of cefepime plus a fluoroquinolone for treating bone and joint infections caused by Gram-negative bacilli (GNB) in 28 patients. Intra-operative cultures yielded primarily Pseudomonas spp. and Enterobacter cloacae. Full recovery (cure) was observed in 79% of patients. There were no serious adverse effects and no resistant organisms were isolated. The results of the study confirmed the safety and effectiveness of cefepime combined with a fluoroquinolone for the treatment of bone and joint infections caused by Gram-negative bacilli.
引用
收藏
页码：1030 / 1033
页数：5
相关论文
共 20 条
  • [1] CEFTAZIDIME AS SINGLE-AGENT THERAPY FOR GRAM-NEGATIVE AEROBIC BACILLARY OSTEOMYELITIS
    BACH, MC
    COCCHETTO, DM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) : 1605 - 1608
  • [2] Diffusion of cefepime into cancellous and cortical bone tissue
    Breilh, D
    Boselli, E
    Bel, JC
    Chassard, D
    Saux, MC
    Allaouchiche, B
    [J]. JOURNAL OF CHEMOTHERAPY, 2003, 15 (02) : 134 - 138
  • [3] TREATMENT OF PSEUDOMONAS-AERUGINOSA-INFECTED ORTHOPEDIC PROSTHESES WITH CEFTAZIDIME CIPROFLOXACIN ANTIBIOTIC COMBINATION
    BROUQUI, P
    ROUSSEAU, MC
    STEIN, A
    DRANCOURT, M
    RAOULT, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (11) : 2423 - 2425
  • [4] DRANCOURT M, 1982, ANTIMICROB AGENTS CH, V21, P62
  • [5] In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains
    Erdem, I
    Kucukercan, M
    Ceran, N
    [J]. CHEMOTHERAPY, 2003, 49 (06) : 294 - 297
  • [6] Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up
    Galanakis, N
    Giamarellou, H
    Moussas, T
    Dounis, E
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) : 241 - 246
  • [7] Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis
    Greenberg, RN
    Newman, MT
    Shariaty, S
    Pectol, RW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) : 164 - 166
  • [8] In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa
    Ishida, H
    Ishida, Y
    Kurosaka, Y
    Otani, T
    Sato, K
    Kobayashi, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) : 1641 - 1645
  • [9] Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates
    Jung, R
    Husain, M
    Choi, MK
    Fish, DN
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) : 1055 - 1057
  • [10] IMIPENEM CILASTATIN IN THE TREATMENT OF OSTEOMYELITIS
    MACGREGOR, RR
    GENTRY, LO
    [J]. AMERICAN JOURNAL OF MEDICINE, 1985, 78 (6A) : 100 - 103
12